Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee

Tempest Therapeutics, Inc.

Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.
Retained MTS Health Partners to evaluate M&A, partnerships, licensing or other transactions.
Amezalpat (TPST-1120) Phase 3-ready with FDA and EMA interactions; Orphan Drug and Fast Track designations in HCC.
TPST-1495 received FDA 'Study May Proceed' for Phase 2 in FAP; data expected 2026.
Company cites unavailable capital markets as reason to seek a strategic partner.

item 1.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-076938
form_type: 8-K
ticker: TPST
cik: 0001544227
company_name: Tempest Therapeutics, Inc.
filed_at: 2025-04-09T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.710921+00:00
generated_at: 2026-05-23T18:17:24.230049+00:00
sec_items: ["1.02", "7.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-076938
json_url: https://secwatch.observer/filing/0001193125-25-076938.json
markdown_url: https://secwatch.observer/filing/0001193125-25-076938.md
text_url: https://secwatch.observer/filing/0001193125-25-076938.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/0001193125-25-076938-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/d906762d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-076938

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.